(Associate Editor: Paul Thomas).
Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde
Version of Record online: 23 DEC 2013
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology
Volume 19, Issue 1, pages 74–79, January 2014
How to Cite
Antus, B., Harnasi, G., Drozdovszky, O. and Barta, I. (2014), Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde. Respirology, 19: 74–79. doi: 10.1111/resp.12155
- Issue online: 23 DEC 2013
- Version of Record online: 23 DEC 2013
- Accepted manuscript online: 8 JUL 2013 07:11AM EST
- Manuscript Accepted: 16 JUN 2013
- Manuscript Revised: 13 JUN 2013
- Manuscript Revised: 10 JUN 2013
- Manuscript Revised: 5 JUN 2013
- Manuscript Revised: 13 MAY 2013
- Manuscript Revised: 16 APR 2013
- Manuscript Revised: 1 APR 2013
- Manuscript Received: 15 FEB 2013
- Hungarian National Scientific Foundation. Grant Number: K83338
- chronic obstructive pulmonary disease;
- exhaled breath condensate;
- oxidative stress;
Background and objective
Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). In this longitudinal study changes in the level of malondialdehyde (MDA), an end product of polyunsaturated fatty acid peroxidation, were investigated in the airways of patients with acute exacerbation of COPD (AECOPD).
Levels of MDA were measured in sputum and exhaled breath condensate (EBC) of 34 COPD patients at the time of hospital admission due to an acute exacerbation of the disease, and again following treatment at the time of hospital discharge. MDA was also assessed in 21 stable patients with COPD and 20 healthy controls. Measurements were performed using high-performance liquid chromatography.
Sputum MDA levels were significantly increased in AECOPD (220.0 ± 17.5 nmol/L) compared with stable disease (144.6 ± 14.3 nmol/L, P < 0.01) and healthy controls (85.9 ± 11.3 nmol/L, P < 0.001). MDA levels decreased after treatment (190.7 ± 16.3 nmol/L, P < 0.05). In contrast to sputum, EBC MDA levels were comparable between controls, stable COPD patients and AECOPD patients (73.1 ± 5.1 nmol/L, 96.1 ± 11.6 nmol/L and 93.3 ± 7.6 nmol/L, P = NS). Measurement of MDA had good repeatability in both sputum and EBC, but the between-day variability was considerably higher in EBC. Sputum induction did not influence MDA levels.
MDA in sputum, but not in EBC, appears to be a useful marker for monitoring exacerbation-associated oxidative stress in AECOPD.